JP2001507577A - 哺乳動物の遺伝子に変異を導入するためのベクターおよび方法 - Google Patents
哺乳動物の遺伝子に変異を導入するためのベクターおよび方法Info
- Publication number
- JP2001507577A JP2001507577A JP53024298A JP53024298A JP2001507577A JP 2001507577 A JP2001507577 A JP 2001507577A JP 53024298 A JP53024298 A JP 53024298A JP 53024298 A JP53024298 A JP 53024298A JP 2001507577 A JP2001507577 A JP 2001507577A
- Authority
- JP
- Japan
- Prior art keywords
- gene
- sequence
- cell
- retroviral vector
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 231
- 239000013598 vector Substances 0.000 title claims abstract description 123
- 238000000034 method Methods 0.000 title claims abstract description 104
- 230000035772 mutation Effects 0.000 title claims description 20
- 210000004027 cell Anatomy 0.000 claims abstract description 153
- 230000001177 retroviral effect Effects 0.000 claims abstract description 90
- 230000005030 transcription termination Effects 0.000 claims abstract description 24
- 210000004962 mammalian cell Anatomy 0.000 claims abstract description 16
- 238000004806 packaging method and process Methods 0.000 claims abstract description 14
- 241001465754 Metazoa Species 0.000 claims description 50
- 102000004169 proteins and genes Human genes 0.000 claims description 44
- 239000004098 Tetracycline Substances 0.000 claims description 35
- 229960002180 tetracycline Drugs 0.000 claims description 35
- 229930101283 tetracycline Natural products 0.000 claims description 35
- 235000019364 tetracycline Nutrition 0.000 claims description 35
- 150000003522 tetracyclines Chemical class 0.000 claims description 35
- 241001430294 unidentified retrovirus Species 0.000 claims description 35
- 239000003550 marker Substances 0.000 claims description 30
- 230000003213 activating effect Effects 0.000 claims description 27
- 230000014509 gene expression Effects 0.000 claims description 27
- 239000005090 green fluorescent protein Substances 0.000 claims description 23
- 230000009261 transgenic effect Effects 0.000 claims description 23
- 108020004414 DNA Proteins 0.000 claims description 20
- 230000010354 integration Effects 0.000 claims description 20
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 16
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 16
- 231100000350 mutagenesis Toxicity 0.000 claims description 11
- 210000000130 stem cell Anatomy 0.000 claims description 11
- 108700008625 Reporter Genes Proteins 0.000 claims description 10
- 238000002703 mutagenesis Methods 0.000 claims description 10
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 claims description 9
- 241000700605 Viruses Species 0.000 claims description 8
- 230000003834 intracellular effect Effects 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 6
- 229930193140 Neomycin Natural products 0.000 claims description 6
- 229960004927 neomycin Drugs 0.000 claims description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 5
- 108091005971 Wild-type GFP Proteins 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 241000713869 Moloney murine leukemia virus Species 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims description 3
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 108010091086 Recombinases Proteins 0.000 claims description 3
- 102000018120 Recombinases Human genes 0.000 claims description 3
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 3
- 238000009396 hybridization Methods 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 25
- 241000699670 Mus sp. Species 0.000 description 21
- 238000003780 insertion Methods 0.000 description 20
- 230000037431 insertion Effects 0.000 description 20
- 239000000370 acceptor Substances 0.000 description 14
- 230000008569 process Effects 0.000 description 14
- 238000013459 approach Methods 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 108090000994 Catalytic RNA Proteins 0.000 description 11
- 102000053642 Catalytic RNA Human genes 0.000 description 10
- 108091092562 ribozyme Proteins 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 108700019146 Transgenes Proteins 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 210000000349 chromosome Anatomy 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000002779 inactivation Effects 0.000 description 5
- 231100000299 mutagenicity Toxicity 0.000 description 5
- 230000007886 mutagenicity Effects 0.000 description 5
- 238000011830 transgenic mouse model Methods 0.000 description 5
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 4
- 108700020796 Oncogene Proteins 0.000 description 4
- 101710139464 Phosphoglycerate kinase 1 Proteins 0.000 description 4
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 230000000779 depleting effect Effects 0.000 description 4
- 108091006104 gene-regulatory proteins Proteins 0.000 description 4
- 102000034356 gene-regulatory proteins Human genes 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 3
- 102220566687 GDNF family receptor alpha-1_F64L_mutation Human genes 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000001613 neoplastic effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 241000219194 Arabidopsis Species 0.000 description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 108010051219 Cre recombinase Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000702191 Escherichia virus P1 Species 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 102220566451 GDNF family receptor alpha-1_Y66H_mutation Human genes 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000005014 ectopic expression Effects 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 102000034287 fluorescent proteins Human genes 0.000 description 2
- 108091006047 fluorescent proteins Proteins 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000010230 functional analysis Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000003471 mutagenic agent Substances 0.000 description 2
- 231100000707 mutagenic chemical Toxicity 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- 101100068321 Aequorea victoria GFP gene Proteins 0.000 description 1
- 241001516864 Allende Species 0.000 description 1
- 241000156724 Antirhea Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000212384 Bifora Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 240000001546 Byrsonima crassifolia Species 0.000 description 1
- 235000003197 Byrsonima crassifolia Nutrition 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 241000710188 Encephalomyocarditis virus Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010046276 FLP recombinase Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101000579126 Mus musculus Phosphoglycerate kinase 1 Proteins 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 241000511989 Neomys Species 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000014450 RNA Polymerase III Human genes 0.000 description 1
- 108010078067 RNA Polymerase III Proteins 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000235343 Saccharomycetales Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 241000711517 Torovirus Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- IKBJGZQVVVXCEQ-UHFFFAOYSA-N efonidipine hydrochloride Chemical compound Cl.CCO.CC=1NC(C)=C(C(=O)OCCN(CC=2C=CC=CC=2)C=2C=CC=CC=2)C(C=2C=C(C=CC=2)[N+]([O-])=O)C=1P1(=O)OCC(C)(C)CO1 IKBJGZQVVVXCEQ-UHFFFAOYSA-N 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 101150009272 gfo gene Proteins 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002743 insertional mutagenesis Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000006525 intracellular process Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 210000000472 morula Anatomy 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 150000003017 phosphorus Chemical class 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 102220094076 rs63750214 Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 108091029842 small nuclear ribonucleic acid Proteins 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 101150003509 tag gene Proteins 0.000 description 1
- 238000012731 temporal analysis Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000003014 totipotent stem cell Anatomy 0.000 description 1
- 230000013715 transcription antitermination Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011820 transgenic animal model Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 238000010451 viral insertion Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.哺乳動物の遺伝子に突然変異を誘発する方法であって、 前記哺乳動物細胞のゲノム中にレトロウイルスベクターを組み込むことが可能 な条件下で該レトロウイルスベクターを導入する導入工程を含み、 前記レトロウイルスベクターがスプライスアクセプター配列、転写終結配列、 レトロウイルスパッケージングおよび組み込み配列を含む、突然変異誘発方法。 2.前記レトロウイルスベクターが、モロニーマウス白血病ウイルス配列由来 のパッケージング配列および組み込み配列を含む、請求の範囲1記載の方法。 3.前記レトロウイルスベクターが、哺乳動物細胞のプロモーターの制御下で 発現するレポーター遺伝子を含み、 前記レポータ遺伝子が、前記哺乳動物細胞のゲノムに前記ベクターが組み込ま れた状態で、前記プロモーターと制御可能に連結される請求の範囲1記載の方法 。 4.前記レポーター遺伝子が制御蛋白質をコードし、前記制御蛋白質が、検出 可能な遺伝子の発現を調節する能力を有する、請求の範囲3記載の方法。 5.前記制御蛋白質が、活性化蛋白質に融合されたテトラサイクリンリプレッ サーである、請求の範囲4記載の方法。 6.前記活性化蛋白質がVP16である、請求の範囲5記載の方法。 7.前記レトロウイルスベクターが、構成的に発現されるマーカー遺伝子をコ ードするDNA配列を含み、前記マーカー遺伝子が、哺乳動物細胞中で検出 可能である、請求の範囲1記載の方法。 8.前記マーカー遺伝子が、緑色蛍光蛋白質である、請求の範囲7記載の方法 。 9.前記緑色蛍光蛋白質が、野生型緑色蛍光蛋白質と比較して細胞内蛍光が増 強されたものである、請求の範囲8記載の方法。 10.前記緑色蛍光蛋白質が、哺乳動物の選択マーカーと融合されたものである 、請求の範囲8記載の方法。 11.前記哺乳動物の選択マーカーが、ネオマイシン耐性をコードする、請求の 範囲9記載の方法。 12.前記レトロウイルスベクターが、酵母のVDE DNAエンドヌクレアーゼ由来 の認識配列を含む、請求の範囲1記載の方法。 13.前記レトロウイルスベクターが、組換え酵素によって認識される配列を含 む、請求の範囲1記載の方法。 14.前記配列が、loxP配列である、請求の範囲13記載の方法。 15.前記哺乳動物が、マウスである、請求の範囲1記載の方法。 16.前記細胞が、幹細胞である、請求の範囲1記載の方法。 17.前記幹細胞が、胚性幹細胞である、請求の範囲16記載の方法。 18.スプライスアクセプター配列、転写終結配列、レトロウイルスパッケ ージングおよび組み込み配列を含むレトロウイルスベクター。 19.前記レトロウイルスベクターが、モロニーマウス白血病ウイルス配列由来 のパッケージングおよび組み込み配列を含む、請求の範囲18記載のレトロウイル スベクター。 20.前記レトロウイルスベクターが、哺乳動物細胞のプロモーターの制御下で 発現するレポーター遺伝子を含み、前記哺乳動物細胞のゲノムに前記ベクターが 組み込まれた状態で、前記レポーター遺伝子が前記プロモーターの支配下にある 、請求の範囲18記載のレトロウイルスベクター。 21.前記レポーター遺伝子が制御蛋白質をコードし、前記制御蛋白質が、検出 可能な遺伝子の発現を調節する能力を有する、請求の範囲20記載のレトロウイル スベクター。 22.前記制御蛋白質が、活性化蛋白質に融合されたテトラサイクリンリプレッ サーである、請求の範囲21記載のレトロウイルスベクター。 23.前記活性化蛋白質がVP16である、請求の範囲22記載のレトロウイルスベク ター。 24.前記検出可能な遺伝子が、テトラサイクリンオペレーターの調節下にある 、請求の範囲22記載のレトロウイルスベクター。 25.構成的に発現されるマーカー遺伝子をコードするDNA配列を含み、前記マ ーカー遺伝子が、哺乳動物細胞中で検出可能である、請求の範囲18記載のレトロ ウイルスベクター。 26.前記マーカー遺伝子が、緑色蛍光蛋白質である、請求の範囲25記載の レトロウイルスベクター。 27.前記緑色蛍光蛋白質が、野生型緑色蛍光蛋白質と比較して細胞内蛍光が増 強されたものである、請求の範囲26記載のレトロウイルスベクター。 28.前記緑色蛍光蛋白質が、哺乳動物の選択マーカーと融合されたものである 、請求の範囲26記載のレトロウイルスベクター。 29.前記哺乳動物の選択マーカーが、ネオマイシン耐性をコードする、請求の 範囲28記載のレトロウイルスベクター。 30.酵母のVDE DNAエンドヌクレアーゼ由来の認識配列を含む、請求の範囲18 記載のレトロウイルスベクター。 31.組換え酵素によって認識される配列を含む、請求の範囲18記載のレトロウ イルスベクター。 32.前記配列が、loxP配列である、請求の範囲31記載のレトロウイルスベクタ ー。 33.請求の範囲18記載のレトロウイルスベクターを保持する細胞。 34.請求の範囲18記載のレトロウイルスベクターを含む、ヒト以外のトランス ジェニック動物。 35.前記動物がマウスである、請求の範囲34記載のヒト以外のトランスジェニ ック動物。 36.請求の範囲1記載の方法で作製された、変異哺乳動物遺伝子ライブラ リー。 37.請求の範囲1記載の方法で作製された、変異哺乳動物遺伝子ライブラリー を保持する細胞。 38.前記細胞が幹細胞である、請求の範囲37記載の細胞。 39.レトロウイルスベクターを保持する細胞を同定する方法であって、 (a)プライスアクセプター配列、転写終結配列、レトロウイルスパッケージ ングおよび組み込み配列を含むレトロウイルスベクターを、哺乳動物細胞のゲノ ム中に前記レトロウイルスベクターが組み込まれることが可能な条件下で、前記 細胞集団へ導入する工程、および、 (b)前記マーカー遺伝子の発現の検出により、前記レトロウイルスベクター を含有する前記細胞を同定する工程、と含む、細胞同定方法。 40.前記の細胞が幹細胞である、請求の範囲39記載の方法。 41.前記マーカー遺伝子が緑色蛍光蛋白質である、請求の範囲39記載の方法。 42.前記緑色蛍光蛋白質が、野生型緑色蛍光蛋白質と比較して細胞内蛍光が増 強されたものである、請求の範囲41記載の方法。 43.変異哺乳動物遺伝子を同定する方法であって、 (a)プライスアクセプター配列、転写終結配列、レトロウイルスパッケージ ングおよび組み込み配列を含むレトロウイルスベクターを、哺乳動物細胞のゲノ ム中に前記レトロウイルスベクターが組み込まれることが可能な条件下で前記ベ クターを前記細胞集団へ導入する工程、 (b)前記細胞集団から前記ゲノムDNAを単離する工程、 (c)前記レトロウイルス配列の、少なくともその一部を基にしたプライマー を使用し、前記ゲノムDNAを増幅する工程、および、 (d)前記変異哺乳動物遺伝子を、野生型塩基配列との相同性によって同定す る工程と、を含む、変異哺乳動物遺伝子の同定方法。 44.前記細胞が幹細胞である、請求の範囲43記載の方法。 45.前記配列の相同性が、ハイブリダイゼーション技術によって同定される、 請求の範囲43記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3409496P | 1996-12-31 | 1996-12-31 | |
US60/034,094 | 1996-12-31 | ||
PCT/US1997/023956 WO1998029533A1 (en) | 1996-12-31 | 1997-12-31 | Vectors and methods for the mutagenesis of mammalian genes |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2001507577A true JP2001507577A (ja) | 2001-06-12 |
Family
ID=21874269
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53024298A Ceased JP2001507577A (ja) | 1996-12-31 | 1997-12-31 | 哺乳動物の遺伝子に変異を導入するためのベクターおよび方法 |
Country Status (6)
Country | Link |
---|---|
US (6) | US6228639B1 (ja) |
EP (1) | EP0951533A4 (ja) |
JP (1) | JP2001507577A (ja) |
AU (1) | AU736267B2 (ja) |
CA (1) | CA2276529A1 (ja) |
WO (1) | WO1998029533A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013051934A (ja) * | 2011-09-06 | 2013-03-21 | National Institutes Of Natural Sciences | テトラサイクリン遺伝子発現誘導システムにおける発現量を増幅させる遺伝子座とノックインによる増幅の効果 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003300776A1 (en) * | 2002-09-09 | 2004-05-25 | Omeros Corporation | G protein coupled receptors and uses thereof |
US20080260744A1 (en) * | 2002-09-09 | 2008-10-23 | Omeros Corporation | G protein coupled receptors and uses thereof |
US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
US7205148B2 (en) * | 2003-06-11 | 2007-04-17 | Regeneron Pharmaceuticals, Inc. | Genome mutation by intron insertion into an embryonic stem cell genome |
GB0325284D0 (en) * | 2003-10-29 | 2003-12-03 | Forinnova As | Methods of identifying active genes |
CN101031655A (zh) | 2004-07-26 | 2007-09-05 | 陶氏环球技术公司 | 通过株工程改进蛋白表达的方法 |
EP1924686A4 (en) | 2005-08-09 | 2009-11-11 | Revivicor Inc | TRANSGENIC NAILS EXPRESSING CTLA4-IG AND USES THEREOF |
WO2007106571A2 (en) * | 2006-03-15 | 2007-09-20 | Soper Bryan R | Methods of screening for and mapping phenotypic and genotypic variations in cells |
US20070292842A1 (en) * | 2006-06-14 | 2007-12-20 | Fulmer-Smentek Stephanie B | Detection of viral or viral vector integration sites in genomic DNA |
WO2008134461A2 (en) | 2007-04-27 | 2008-11-06 | Dow Global Technologies, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
US9580719B2 (en) | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
JP7460643B2 (ja) | 2018-10-16 | 2024-04-02 | ブルーアレル, エルエルシー | 遺伝子へのdnaの標的化挿入のための方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5364783A (en) * | 1990-05-14 | 1994-11-15 | Massachusetts Institute Of Technology | Retrovirus promoter-trap vectors |
NZ265091A (en) * | 1993-04-21 | 1997-07-27 | Univ Edinburgh | Dna constructs for inserting heterologous gene sequences into a host genome |
CA2165162C (en) | 1993-06-14 | 2000-05-23 | Hermann Bujard | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
US5464758A (en) * | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
US5912411A (en) | 1993-06-14 | 1999-06-15 | University Of Heidelberg | Mice transgenic for a tetracycline-inducible transcriptional activator |
US5654168A (en) * | 1994-07-01 | 1997-08-05 | Basf Aktiengesellschaft | Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units |
US5888981A (en) | 1993-06-14 | 1999-03-30 | Basf Aktiengesellschaft | Methods for regulating gene expression |
US5695995A (en) * | 1994-05-06 | 1997-12-09 | Fred Hutchinson Cancer Research Center | Neurogenic differentiation (neurod) genes |
US5693508A (en) * | 1994-11-08 | 1997-12-02 | Chang; Lung-Ji | Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats |
US5922601A (en) | 1995-01-19 | 1999-07-13 | Biotransplant, Inc. | High efficiency gene trap selection of regulated genetic loci |
EP0821740A1 (en) * | 1995-04-20 | 1998-02-04 | Chiron Corporation | High efficiency ex vivo transduction of hematopoietic stem cells by recombinant retroviral preparations |
US5629159A (en) * | 1995-06-07 | 1997-05-13 | California Institute Of Technology | Immortalization and disimmortalization of cells |
US6139833A (en) | 1997-08-08 | 2000-10-31 | Lexicon Genetics Incorporated | Targeted gene discovery |
US6207371B1 (en) | 1996-10-04 | 2001-03-27 | Lexicon Genetics Incorporated | Indexed library of cells containing genomic modifications and methods of making and utilizing the same |
US5965995A (en) * | 1997-09-18 | 1999-10-12 | Allen-Bradley Company, Llc | Transient inductance tuner for motor control |
-
1997
- 1997-12-31 JP JP53024298A patent/JP2001507577A/ja not_active Ceased
- 1997-12-31 CA CA002276529A patent/CA2276529A1/en not_active Abandoned
- 1997-12-31 WO PCT/US1997/023956 patent/WO1998029533A1/en not_active Application Discontinuation
- 1997-12-31 US US09/002,046 patent/US6228639B1/en not_active Expired - Lifetime
- 1997-12-31 AU AU58079/98A patent/AU736267B2/en not_active Ceased
- 1997-12-31 EP EP97954255A patent/EP0951533A4/en not_active Withdrawn
-
2001
- 2001-05-01 US US09/847,090 patent/US20020012996A1/en not_active Abandoned
- 2001-08-16 US US09/931,957 patent/US20010056581A1/en not_active Abandoned
- 2001-10-17 US US09/982,586 patent/US20020083481A1/en not_active Abandoned
- 2001-12-10 US US10/015,960 patent/US20020115210A1/en not_active Abandoned
-
2004
- 2004-10-27 US US10/974,603 patent/US8389795B2/en not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013051934A (ja) * | 2011-09-06 | 2013-03-21 | National Institutes Of Natural Sciences | テトラサイクリン遺伝子発現誘導システムにおける発現量を増幅させる遺伝子座とノックインによる増幅の効果 |
Also Published As
Publication number | Publication date |
---|---|
US20050059078A1 (en) | 2005-03-17 |
AU736267B2 (en) | 2001-07-26 |
US20020115210A1 (en) | 2002-08-22 |
US20010056581A1 (en) | 2001-12-27 |
US6228639B1 (en) | 2001-05-08 |
EP0951533A1 (en) | 1999-10-27 |
AU5807998A (en) | 1998-07-31 |
WO1998029533A1 (en) | 1998-07-09 |
CA2276529A1 (en) | 1998-07-09 |
EP0951533A4 (en) | 2004-08-18 |
US20020012996A1 (en) | 2002-01-31 |
US20020083481A1 (en) | 2002-06-27 |
US8389795B2 (en) | 2013-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5922601A (en) | High efficiency gene trap selection of regulated genetic loci | |
US6207371B1 (en) | Indexed library of cells containing genomic modifications and methods of making and utilizing the same | |
US6436707B1 (en) | Vectors for gene mutagenesis and gene discovery | |
JP2001507577A (ja) | 哺乳動物の遺伝子に変異を導入するためのベクターおよび方法 | |
Reddy et al. | Fluorescence-activated sorting of totipotent embryonic stem cells expressing developmentally regulated lacZ fusion genes. | |
JP2002509727A (ja) | 遺伝子突然変異誘発および遺伝子発見のためのベクター | |
US20030143597A1 (en) | Methods for making polynucleotide libraries, polynucleotide arrays, and cell libraries for high-throughput genomics analysis | |
US9085767B2 (en) | Enhancer-containing gene trap vectors for random and targeted gene trapping | |
US20070196917A1 (en) | Methods of constructing a gene mutation library and compounds and compositions thereof | |
US6777235B1 (en) | Complementation trap | |
AU778904B2 (en) | Vectors and methods for the mutagenesis of mammalian genes | |
US7767454B2 (en) | Methods for mutating genes in cells using insertional mutagenesis | |
US20040137490A1 (en) | Methods for making polynucleotide libraries, polynucleotide arrays, and cell libraries for high-throughput genomics analysis | |
US20050114913A1 (en) | Methods and compositions for generating homozygous mutations | |
WO2003029473A1 (en) | Genetic tagging strategy for inducing and identifying mutations in a genomic sequence | |
Scherer | An in vitro screen to isolate developmentally regulated genes in mice | |
Battaglino | A genetic screen for developmentally regulated genes in mice | |
CA2295475A1 (en) | Complementation trap |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041227 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070605 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20070608 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070831 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071005 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071001 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071112 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071101 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071210 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20080116 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080226 |